

Parainfluenza Virus Type 2

DAG4703 hPIV

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview Parainfluenza Virus Type 2

Description Infected cell culture supernatant is treated to remove cellular material, further purified by size exclusion

chromatography and concentrated. The antigen is presented in Tris/NaCl buffer at pH 7.4.

Source Vero cell culture

Species hPIV

Immunogen Parainfluenza virus Type 2 - Strain Greer

Inactivation Beta-propiolactone treatment. Inactivity is confirmed by

attempted growth under original culture conditions. Since no procedure can guarantee absolute sterility, the reagent should be handled with appropriate safety precautions.

Applications By ELISA

PACKAGING

Storage -20° C to -80°C. Avoid repeated freeze-thaw cycles

Shipping 10 years from manufacture

BACKGROUND

Introduction HPIV is genetically and antigenically divided into types 1 to 4. HPIV 1 to HPIV 3 are major causes of

lowerrespiratory infections in infants, young children, the immunocompromised, thechronically ill, and the elderly. Each subtype can cause somewhat uniqueclinical diseases in different hosts. HPIV are enveloped and of medium size(150 to 250 nm), and their RNA genome is in the negative sense. These virusesbelong to the Paramyxoviridae family, one of the largest and most rapidlygrowing groups of viruses causing significant human and veterinary disease. HPIV are closely related to recently

discovered megamyxoviruses (Hendra andNipah viruses) and metapneumovirus.

Keywords Human parainfluenza viruses; HPIVs;HPIV-2; HPIV; Human Parainfluenza virus 2; Paramyxoviridae

REFERENCES

1. Sato M, Wright PF (October 2008). "Current status of vaccines for parainfluenza virus infections". Pediatr. Infect. Dis. J. 27 (10 Suppl): S123–5.

2. Sable CA, Hayden FG (December 1995). "Orthomyxoviral and paramyxoviral infections in transplant patients". Infect. Dis. Clin. North Am. 9 (4): 987–1003